New drug offers hope for rare sarcoma patients

NCT ID NCT06942442

Recruiting now Disease control Sponsor: Sarcoma Alliance for Research through Collaboration Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 26 times

Summary

This study tests a drug called tebentafusp in people with a rare type of cancer called clear cell sarcoma that has spread or cannot be removed by surgery. Only people with a specific genetic marker (HLA-A*02:01) can join. The main goal is to see if the drug can stop the cancer from growing for at least 24 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HLA-A*0201 POSITIVE CELLS PRESENT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Southern California - Norris Cancer Center
RECRUITING

Los Angeles, California, 90033, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CLEAR CELL SARCOMA (CCS) HLA-A*0201 POSITIVE CELLS PRESENT